Article
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
Clinical lung cancer - 1 Mar 2022
Koopman Bart, Groen Harry J M, Schuuring Ed, Hiltermann T Jeroen N, Timens Wim, den Dunnen Wilfred F A, van den Berg Anke, Ter Elst Arja, van Kruchten Michel, Kluiver Joost L, Hiddinga Birgitta I, Hijmering-Kappelle Lucie B M, Groves Matthew R, Vilacha Juliana F, van Kempen Léon C, van der Wekken Anthonie J
Abstract excerpt
INTRODUCTION: Non-small cell lung cancer (NSCLC) patients with Anaplastic Lymphoma Kinase (ALK) gene fusions respond well to ALK inhibitors but commonly develop on-target resistance mutations. The objective of this study is to collect clinical evidence for subsequent treatment with ALK inhibitors. PATIENTS AND METHODS: Local experience with on-target ALK resistance mutations and review of the literature...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.